Physician profile
David Mandil
NPI 1093179285
$6,222.29
in general payments reported to CMS, 2019-2025
21 companies · $20.54 in 2025
The $20.54 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $253 · 2021: $3,639 · 2022: $1,571 · 2023: $225 · 2024: $119 · 2025: $20.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $1,694.32 | 2021-2024 | Portfolio |
| Arthrex, INC. | $1,363.84 | 2021 | |
| Gotham Surgical Solutions & Devices, INC. | $1,200.00 | 2022 | |
| Seapearl East, INC | $507.44 | 2021 | |
| Stryker Corporation | $490.74 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $371.53 | 2020-2022 | |
| Ossio INC | $166.67 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2020 | |
| Mindray Ds USA, INC. | $65.38 | 2022-2023 | Te7 Max, Te X |
| Suvon Surgical LLC | $58.98 | 2022 | |
| Kerecis Limited | $38.41 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Grt US Holding, INC. | $24.58 | 2022 | |
| Abbvie INC. | $20.54 | 2025 | |
| Musculoskeletal Transplant Foundation INC. | $17.33 | 2021 | |
| Horizon Therapeutics Plc | $17.16 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $15.62 | 2020 | |
| Carestream Health, INC. | $14.89 | 2020 | |
| Axogen | $14.67 | 2021 | |
| Trevena, INC. | $12.85 | 2021 | |
| Advanced Oxygen Therapy INC. | $2.34 | 2023 | Topical Oxygen Chamber For Extremities |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$300,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mandil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.